AbCellera Biologics (ABCL) Common Equity (2020 - 2026)

AbCellera Biologics' Common Equity history runs 7 years deep, the most recent figure standing at $938.1 million for Q1 2026.

• Quarterly Common Equity fell 8.3% year-over-year to $938.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $938.1 million (down 8.3% YoY) and the FY2025 annual result came in at $966.9 million, down 8.44% from the prior year.
• Common Equity was $938.1 million for Q1 2026 at AbCellera Biologics, down from $966.9 million in the prior quarter.
• Across five years, Common Equity topped out at $1.3 billion in Q3 2022 and bottomed at $938.1 million in Q1 2026.
• A 5-year average of $1.1 billion and a median of $1.1 billion in 2024 frame the typical range for Common Equity.
• Annual changes were most pronounced in 2022 — Common Equity surged 31.13% — and 2025, when it decreased 10.58%.
• AbCellera Biologics' Common Equity stood at $1.2 billion in 2022, then slipped by 6.56% to $1.2 billion in 2023, then declined by 8.35% to $1.1 billion in 2024, then retreated by 8.44% to $966.9 million in 2025, then retreated by 2.98% to $938.1 million in 2026.
• Business Quant data shows ABCL's Common Equity at $938.1 million in Q1 2026, $966.9 million in Q4 2025, and $964.0 million in Q3 2025.